FOXO Signaling Pathways as Therapeutic Targets in Cancer

Many transcription factors play a key role in cellular differentiation and the delineation of cell phenotype. Transcription factors are regulated by phosphorylation, ubiquitination, acetylation/deacetylation and interactions between two or more proteins controlling multiple signaling pathways. These pathways regulate different physiological processes and pathological events, such as cancer and other diseases. The Forkhead box O (FOXO) is one subfamily of the fork head transcription factor family with important roles in cell fate decisions and this subfamily is also suggested to play a pivotal functional role as a tumor suppressor in a wide range of cancers. During apoptosis, FOXOs are involved in mitochondria-dependent and -independent processes triggering the expression of death receptor ligands like Fas ligand, TNF apoptosis ligand and Bcl‑XL, bNIP3, Bim from Bcl-2 family members. Different types of growth factors like insulin play a vital role in the regulation of FOXOs. The most important pathway interacting with FOXO in different types of cancers is the PI3K/AKT pathway. Some other important pathways such as the Ras-MEK-ERK, IKK and AMPK pathways are also associated with FOXOs in tumorigenesis. Therapeutically targeting the FOXO signaling pathway(s) could lead to the discovery and development of efficacious agents against some cancers, but this requires an enhanced understanding and knowledge of FOXO transcription factors and their regulation and functioning. This review focused on the current understanding of cell biology of FOXO transcription factors which relates to their potential role as targets for the treatment and prevention of human cancers. We also discuss drugs which are currently being used for cancer treatment along with their target pathways and also point out some potential drawbacks of those drugs, which further signifies the need for development of new drug strategies in the field of cancer treatment.

[1]  ASHP Therapeutic Position Statements 685 Therapeutic Monitoring of Vancomycin in Adult Patients : A Consensus Review of the American Society of HealthSystem Pharmacists , 2018 .

[2]  Fengxia Yan,et al.  Amiodarone-Induced Retinal Neuronal Cell Apoptosis Attenuated by IGF-1 via Counter Regulation of the PI3k/Akt/FoxO3a Pathway , 2016, Molecular Neurobiology.

[3]  Fengxia Yan,et al.  Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  M. Buchfelder,et al.  Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency , 2016, Oncoscience.

[5]  Wenhua Zheng,et al.  Evaluation of the potential synergism of imatinib‐related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response , 2016, The Journal of pharmacy and pharmacology.

[6]  Limei Qin,et al.  miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1 , 2016, Tumor Biology.

[7]  M. Kamal,et al.  Telomeric Repeat Containing RNA (TERRA): Aging and Cancer. , 2015, CNS & neurological disorders drug targets.

[8]  N. Wheate,et al.  The state-of-play and future of platinum drugs. , 2015, Endocrine-related cancer.

[9]  P. Urbánek,et al.  Redox regulation of FoxO transcription factors , 2015, Redox biology.

[10]  MiR-135b promotes proliferation and invasion of osteosarcoma cells via targeting FOXO1 , 2015, Molecular and Cellular Biochemistry.

[11]  MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1 , 2014, BMC Cancer.

[12]  S. S. Yadav,et al.  Down Regulation of FOXO1 Promotes Cell Proliferation in Cervical Cancer , 2014, Journal of Cancer.

[13]  D. Graves,et al.  FOXO Transcription Factors: Their Clinical Significance and Regulation , 2014, BioMed research international.

[14]  David A. Frank,et al.  Targeting transcription factors: promising new strategies for cancer therapy , 2013, Current opinion in oncology.

[15]  S. Andò,et al.  The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness , 2013, Cell cycle.

[16]  Sang-Mo Kwon,et al.  Angiogenesis and Its Therapeutic Opportunities , 2013, Mediators of inflammation.

[17]  J. Cheng,et al.  IKBKE Phosphorylation and Inhibition of FOXO3a: A Mechanism of IKBKE Oncogenic Function , 2013, PloS one.

[18]  Rikang Wang,et al.  The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells , 2013, Psychopharmacology.

[19]  R. Young,et al.  Transcriptional Regulation and Its Misregulation in Disease , 2013, Cell.

[20]  X. Mao,et al.  Upregulation of MircoRNA-370 Induces Proliferation in Human Prostate Cancer Cells by Downregulating the Transcription Factor FOXO1 , 2012, PloS one.

[21]  Hui Zhang,et al.  miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. , 2012, Oncology letters.

[22]  Harald J. Maier,et al.  FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. , 2012, Blood.

[23]  D. Xing,et al.  A pathway from JNK through decreased ERK and Akt activities for FOXO3a nuclear translocation in response to UV irradiation , 2012, Journal of cellular physiology.

[24]  G. Poli,et al.  Tumor suppressor genes and ROS: complex networks of interactions. , 2012, Free radical biology & medicine.

[25]  K. Tachibana,et al.  FoxO3a Functions as a Key Integrator of Cellular Signals That Control Glioblastoma Stem‐like Cell Differentiation and Tumorigenicity , 2011, Stem cells.

[26]  A. Klagge,et al.  FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. , 2011, The Journal of clinical endocrinology and metabolism.

[27]  Ophelia S. Venturelli,et al.  The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor , 2011, Oncogene.

[28]  W. Kim,et al.  Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules , 2011, BMC Cancer.

[29]  Libing Song,et al.  Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a , 2010, PloS one.

[30]  F. Agou,et al.  IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. , 2010, Blood.

[31]  Lara J. Monteiro,et al.  Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. , 2009, Cancer research.

[32]  F. Barr,et al.  Tumorigenesis and Neoplastic Progression High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human Myoblasts , 2022 .

[33]  C. Kemp,et al.  Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer , 2009, Oncogene.

[34]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[35]  B. White,et al.  Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells , 2009, The Journal of Biological Chemistry.

[36]  A. Toker,et al.  FOXO3a Promotes Tumor Cell Invasion through the Induction of Matrix Metalloproteinases , 2009, Molecular and Cellular Biology.

[37]  K. Maiese,et al.  A “FOXO” in sight: Targeting Foxo proteins from conception to cancer , 2009, Medicinal research reviews.

[38]  D. Polsky,et al.  Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor , 2009, Proceedings of the National Academy of Sciences.

[39]  Yong Zhao,et al.  New insights for FOXO and cell-fate decision in HIV infection and HIV associated neurocognitive disorder. , 2009, Advances in experimental medicine and biology.

[40]  Kenneth Maiese,et al.  Forkhead transcription factors. , 2010 .

[41]  T. Mak,et al.  Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. , 2008, Journal of molecular biology.

[42]  S. Cook,et al.  Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM , 2008, Oncogene.

[43]  E. Lam,et al.  Resist or die: FOXO transcription factors determine the cellular response to chemotherapy , 2008, Cell cycle.

[44]  K. Maiese,et al.  Rogue proliferation versus restorative protection: Where do we draw the line for Wnt and Forkhead signaling? , 2008, Expert opinion on therapeutic targets.

[45]  K. Maiese,et al.  Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies , 2008, Progress in Neurobiology.

[46]  M. Ladanyi,et al.  Identification of PAX3‐FKHR‐regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: Focus on MYCN as a biologically relevant target , 2008, Genes, chromosomes & cancer.

[47]  K. Maiese,et al.  Erythropoietin and oxidative stress. , 2008, Current neurovascular research.

[48]  D. Tindall,et al.  FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.

[49]  E. Lam,et al.  Many forks in the path: cycling with FoxO , 2008, Oncogene.

[50]  A. Brunet,et al.  The FoxO code , 2008, Oncogene.

[51]  M. Essers,et al.  Interaction of FOXO with β-Catenin Inhibits β-Catenin/T Cell Factor Activity* , 2008, Journal of Biological Chemistry.

[52]  K. Maiese.  Diabetic stress: new triumphs and challenges to maintain vascular longevity , 2008, Expert review of cardiovascular therapy.

[53]  C. Emanueli,et al.  Identification of the prosurvival activity of nerve growth factor on cardiac myocytes , 2008, Cell Death and Differentiation.

[54]  G. Mills,et al.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation , 2008, Nature Cell Biology.

[55]  K. Sakamoto,et al.  Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis , 2008, Molecular and Cellular Endocrinology.

[56]  K. Walsh,et al.  Forkhead Transcription Factors and Cardiovascular Biology , 2007 .

[57]  J. Lazarewicz,et al.  Nicotinamide and 1-methylnicotinamide reduce homocysteine neurotoxicity in primary cultures of rat cerebellar granule cells. , 2008, Acta neurobiologiae experimentalis.

[58]  K. Ozawa,et al.  Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia‐derived cell lines via the production of tumor necrosis factor‐related apoptosis‐inducing ligand , 2007, Cancer science.

[59]  K. Maiese,et al.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. , 2007, Histology and histopathology.

[60]  Soyoung Lee,et al.  FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. , 2007, Genes & development.

[61]  E. Lam,et al.  The emerging roles of forkhead box (Fox) proteins in cancer , 2007, Nature Reviews Cancer.

[62]  M. Essafi,et al.  Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a , 2007, Oncogene.

[63]  S. Kane,et al.  Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. , 2007, Cancer research.

[64]  G. Tuteja,et al.  SnapShot:Forkhead Transcription Factors I , 2007, Cell.

[65]  Zhiwei Wang,et al.  Regulation of FOXO3a/β-Catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells* , 2007, Journal of Biological Chemistry.

[66]  K. Maiese,et al.  Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. , 2007, Cellular signalling.

[67]  K. Nowak,et al.  E2F-1 regulates expression of FOXO1 and FOXO3a. , 2007, Biochimica et Biophysica Acta.

[68]  K. Maiese,et al.  Erythropoietin involves the phosphatidylinositol 3‐kinase pathway, 14‐3‐3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity , 2007, British journal of pharmacology.

[69]  S. Armstrong,et al.  FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.

[70]  Yonghong Xiao,et al.  FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis , 2007, Cell.

[71]  R. Mägi,et al.  Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age , 2007, European Journal of Human Genetics.

[72]  Zhiwei Wang,et al.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. , 2007, The Journal of biological chemistry.

[73]  M. Hu,et al.  Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[74]  H. Otu,et al.  A Novel Class of Vascular Endothelial Growth Factor-responsive Genes That Require Forkhead Activity for Expression* , 2006, Journal of Biological Chemistry.

[75]  E. Lam,et al.  Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. , 2006, Molecular endocrinology.

[76]  K. Maiese,et al.  Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of Glycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB , 2006 .

[77]  T. Mak,et al.  Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[78]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[79]  Keshav K. Singh.  Mitochondria Damage Checkpoint, Aging, and Cancer , 2006, Annals of the New York Academy of Sciences.

[80]  K. Maiese,et al.  Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. , 2006, Current neurovascular research.

[81]  Estradiol prevents the focal cerebral ischemic injury-induced decrease of forkhead transcription factors phosphorylation , 2006, Neuroscience Letters.

[82]  H. Shin,et al.  Polymorphisms in FOXO Gene Family and Association Analysis with BMI , 2006, Obesity.

[83]  N. Ahmad,et al.  RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. , 2006, Cancer research.

[84]  K. Maiese,et al.  Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. , 2006, Current neurovascular research.

[85]  R. Coombes,et al.  Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. , 2006, Cancer research.

[86]  E. Greer,et al.  FOXO transcription factors at the interface between longevity and tumor suppression , 2005, Oncogene.

[87]  R. DePinho,et al.  Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. , 2005, The Journal of clinical investigation.

[88]  K. Maiese,et al.  mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through Akt and caspase dependent pathways. , 2005, Current neurovascular research.

[89]  Hendrik C Korswagen,et al.  Functional Interaction Between ß-Catenin and FOXO in Oxidative Stress Signaling , 2005, Science.

[90]  M. Gorospe,et al.  Phosphorylation of p66Shc and forkhead proteins mediates Aβ toxicity , 2005, The Journal of cell biology.

[91]  J. Graff,et al.  The Progression of LNCaP Human Prostate Cancer Cells to Androgen Independence Involves Decreased FOXO3a Expression and Reduced p27KIP1 Promoter Transactivation , 2005, Molecular Cancer Research.

[92]  K. Maiese,et al.  Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease , 2005, Progress in Neurobiology.

[93]  John A. Hall,et al.  mtDNA mutations increase tumorigenicity in prostate cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. Bos,et al.  FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK , 2004, The EMBO journal.

[95]  B. Pettmann,et al.  Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK , 2004, BMC Neuroscience.

[96]  Benjamin R. Arenkiel,et al.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. , 2004, Genes & development.

[97]  K. Maiese,et al.  The NAD+ Precursor Nicotinamide Governs Neuronal Survival During Oxidative Stress Through Protein Kinase B Coupled to FOXO3a and Mitochondrial Membrane Potential , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[98]  Michael G. Kharas,et al.  Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. , 2004, Blood.

[99]  Marten P Smidt,et al.  The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. , 2004, The Biochemical journal.

[100]  J. Griffin,et al.  FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins , 2004, Oncogene.

[101]  Ryuji Kobayashi,et al.  IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a , 2004, Cell.

[102]  K. Maiese,et al.  The Tyrosine Phosphatase SHP2 Modulates MAP Kinase p38 and Caspase 1 and 3 to Foster Neuronal Survival , 2003, Cellular and Molecular Neurobiology.

[103]  Ryuji Kobayashi,et al.  IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. , 2004, Cell.

[104]  C. Sugimoto,et al.  PI3K/Akt and apoptosis: size matters , 2003, Oncogene.

[105]  K. Maiese,et al.  Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity , 2003, Journal of neuroscience research.

[106]  P. Wijchers,et al.  FoxO6, a Novel Member of the FoxO Class of Transcription Factors with Distinct Shuttling Dynamics* , 2003, Journal of Biological Chemistry.

[107]  Hitomi Matsuzaki,et al.  Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[108]  K. Maiese,et al.  Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. , 2003, Molecular pharmacology.

[109]  K. Maiese,et al.  Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. , 2003, Trends in pharmacological sciences.

[110]  A. Cuadrado,et al.  Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner* , 2003, The Journal of Biological Chemistry.

[111]  K. Maiese,et al.  Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase‐mediated pathways , 2003, British journal of pharmacology.

[112]  G. Grosveld,et al.  Pax3-FKHR Knock-In Mice Show Developmental Aberrations but Do Not Develop Tumors , 2002, Molecular and Cellular Biology.

[113]  Geert J. P. L. Kops,et al.  Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress , 2002, Nature.

[114]  S. Catarzi,et al.  The role of H2O2 in the platelet-derived growth factor-induced transcription of the γ-glutamylcysteine synthetase heavy subunit , 2002, Cellular and Molecular Life Sciences CMLS.

[115]  N. Motoyama,et al.  FOXO Forkhead Transcription Factors Induce G2-M Checkpoint in Response to Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[116]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[117]  P. Cohen,et al.  Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion , 2002, The EMBO journal.

[118]  Wenhua Zheng,et al.  FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling , 2002, Journal of neurochemistry.

[119]  P. Cohen,et al.  The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. , 2001, The Biochemical journal.

[120]  K. Maiese,et al.  The Metabotropic Glutamate Receptor System Protects against Ischemic Free Radical Programed Cell Death in Rat Brain Endothelial Cells , 2001 .

[121]  Brian A. Hemmings,et al.  Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a) , 2001, Molecular and Cellular Biology.

[122]  K. Maiese,et al.  The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[123]  R. Quirion,et al.  Insulin-like Growth Factor-1-induced Phosphorylation of the Forkhead Family Transcription Factor FKHRL1 Is Mediated by Akt Kinase in PC12 Cells* , 2000, The Journal of Biological Chemistry.

[124]  J. Lammers,et al.  Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1 , 2000, Molecular and Cellular Biology.

[125]  D. Yee,et al.  Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells , 2000, Oncogene.

[126]  K. Ozawa,et al.  A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. , 2000, Blood.

[127]  D. Accili,et al.  Differential regulation of gene expression by insulin and IGF‐1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR , 2000, The EMBO journal.

[128]  T. Rabbitts,et al.  Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene , 2000, The EMBO journal.

[129]  Y. Suh,et al.  Cell transformation by the superoxide-generating oxidase Mox1 , 1999, Nature.

[130]  P. Cohen,et al.  Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B* , 1999, The Journal of Biological Chemistry.

[131]  D. Accili,et al.  Insulin Stimulates Phosphorylation of the Forkhead Transcription Factor FKHR on Serine 253 through a Wortmannin-sensitive Pathway* , 1999, The Journal of Biological Chemistry.

[132]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[133]  C. Kenyon,et al.  daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. , 1997, Science.

[134]  R. Berger,et al.  AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. , 1997, Blood.

[135]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[136]  J. Zweier,et al.  Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts , 1997, Science.

[137]  Arndt Borkhardt,et al.  Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23) , 1997, Oncogene.

[138]  F. Barr,et al.  The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3 , 1995, Molecular and cellular biology.

[139]  Yalin H. Wei,et al.  Cloning and characterization of the t(X;II) breakpoint from a leukemic cell line identify a new member of the forkhead gene family , 1994, Genes, chromosomes & cancer.

[140]  J. Biegel,et al.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. , 1994, Cancer research.

[141]  B. Emanuel,et al.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[142]  C. Nathan,et al.  Production of large amounts of hydrogen peroxide by human tumor cells. , 1991, Cancer research.

[143]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.